12:00 AM
Apr 28, 2014
 |  BC Week In Review  |  Company News  |  Other News

Bavarian Nordic, U.S. Department of Health and Human Services infectious news

Bavarian Nordic said HHS's Biomedical Advanced Research and Development Authority (BARDA) exercised an option to award $21.9 million under a 2009 contract to develop a freeze-dried formulation of Imvamune smallpox vaccine. The company said the freeze-dried formulation could have a longer shelf life than the liquid frozen formulation and would not require...

Read the full 249 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >